title: Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
authors.forename: Susana
authors.initials: S
authors.lastname: Baltà-Cruz
authors.forename: Mercé
authors.initials: M
authors.lastname: Alsina-Glbert
authors.forename: Ana
authors.initials: A
authors.lastname: Mozos-Rocafort
authors.forename: Carlos
authors.initials: C
authors.lastname: Cervera
authors.forename: Lluís
authors.initials: L
authors.lastname: Colomo-Saperas
authors.forename: Ana
authors.initials: A
authors.lastname: Del Río
authors.forename: Teresa
authors.initials: T
authors.lastname: Estrach-Panella
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016773:Leishmaniasis, Cutaneous / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab